{
    "root": "357db2ca-71fe-dafc-e063-6294a90a8ed4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Citalopram",
    "value": "20250509",
    "ingredients": [
        {
            "name": "COPOVIDONE K25-31",
            "code": "D9C330MD8B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_78913"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "HYPROMELLOSE 2910 (6 MPA.S)",
            "code": "0WZ8WG20P6",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "CITALOPRAM HYDROBROMIDE",
            "code": "I1E9D14F36",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3724"
        }
    ],
    "indications": {
        "text": "citalopram tablets indicated treatment major depressive disorder ( mdd ) adults [ ( 14 ) ] .",
        "doid_entities": [
            {
                "text": "major depressive disorder (DOID:1470)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1470"
            },
            {
                "text": "depressive disorder (DOID:1596)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1596"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer daily without food ( 2 ) . initial 20 mg daily ; one week may increase maximum 40 mg daily ( 2.1 ) . patients greater 60 years age , patients hepatic impairment , cyp2c19 poor metabolizers : maximum recommended 20 mg daily ( 2.2 ) . discontinuing citalopram tablets , reduce gradually ( 2.4 , 5.6 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "citalopram tablets , usp supplied follows : 20 mg tablets \u2013light pink colored , biconvex , capsule shaped film coated tablets debossed \u2018 \u2019 one side score line \u2018 0 \u2019 \u2018 6 \u2019 side . bottles 30 ndc 42708-019-30 storage handling store at20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] .",
    "adverseReactions": "citalopram tablets contraindicated patients : taking , within 14 days stopping , maois ( including maois linezolid intravenous methylene blue ) increased risk serotonin syndrome [ ( 5.3 ) , ( 7 ) ] . taking pimozide risk qt prolongation [ ( 7 ) ] . known hypersensitivity citalopram inactive ingredients citalopram tablets . included angioedema anaphylaxis [ ( 6.2 ) ] .",
    "indications_original": "Citalopram tablets are indicated for the treatment of major depressive disorder (MDD) in adults\n \n  [see\n  \n   Clinical Studies (14)]\n \n  .",
    "contraindications_original": "Administer once daily with or without food ( 2 ) . Initial dosage is 20 mg once daily; after one week may increase to maximum dosage of 40 mg once daily ( 2.1 ). Patients greater than 60 years of age, patients with hepatic impairment, and CYP2C19 poor metabolizers: maximum recommended dosage is 20 mg once daily ( 2.2 ). When discontinuing citalopram tablets, reduce dosage gradually ( 2.4 , 5.6 ).",
    "warningsAndPrecautions_original": "Citalopram tablets, USP are supplied as follows:\n  \n                     \n20 mg Tablets \u2013Light pink colored, biconvex, capsule shaped film coated tablets debossed with \u2018A\u2019 on one side and with a score line in between \u20180\u2019 and \u20186\u2019 on other side.\n  \n                     \nBottles of 30 NDC 42708-019-30\n \n                  Storage and Handling\n  \n                     \nStore at20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Citalopram tablets are contraindicated in patients:\n                  \n                  \n                     taking, or within 14 days of stopping, MAOIs (including MAOIs such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome\n  \n   [see\n   \n    Warnings and Precautions (5.3),\n   \n    Drug Interactions (7)]\n  \n   .\n \n  \n                     taking pimozide because of risk of QT prolongation\n  \n   [see\n   \n    Drug Interactions (7)]\n  \n   .\n  \n   \n                     \n                     with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. Reactions have included angioedema and anaphylaxis\n  \n   [see\n   \n    Adverse Reactions (6.2)].",
    "drug": [
        {
            "name": "Citalopram",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_3723"
        }
    ]
}